Skip to content

Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure

Effect of Normatec Pump for Relief of Leg Edema in Patients With Right Heart Failure: Short- Intermediate- and Long-Term Outcomes

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00834145
Enrollment
30
Registered
2009-02-03
Start date
2009-03-31
Completion date
2009-12-31
Last updated
2009-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cor Pulmonale, Right Heart Failure

Keywords

Edema, Right heart failure, Cor pulmonale, Pump, Leg compression

Brief summary

Mobilization of fluid from the legs with the Normatec pump in patients with right heart failure, may empty the reservoir in the legs from excessive fluid, enabling fluid overload to collect there rather than in the liver or in other third spaces. Thus, we hypothesize that patients will lose weight, feel better, look better, be less prone to infections in their legs and to congestion of the liver.

Detailed description

The protocol will be divided into 2 parts: 1. The initial pumping phase will be an in-hospital study, short term study. Patients will be randomly assigned to conventional/conservative treatment or to pump therapy. Within 24 hours of admission patients assigned to pump therapy will be recruited for the study and will begin therapy according to the protocol outlined in the table below. These patients will not be given diuretics unless required to because of shortness of breath with suspected left heart failure. Individualized programs regarding pumping frequency and pump parameters will be set for each patient and will be adjusted during the first few days and maintained throughout the study unless there is a reason to modify them. Data on both the conventional/conservative and the pump arms of the study will be collected at similar intervals. The duration of the in-hospital period will not be extended because of the study and is expected to be 3-7 days. 2. An intermediate-term study in which the patients from the phase 1 study will be ambulatory. During this phase of the study the effect of continuous maintenance and optimization will be monitored. Patients will come to the hospital for their pumping session at which time the protocol tests will be performed. Patients that were assigned to the conventional/conservative arm in phase 1 will be examined as per protocol at 1, 2 and 3 weeks after admission but BNP levels will be repeated only after the 3rd week. 3. At 3 and 6 months after admission, the long term phase of the study, a systematic investigation regarding repeat hospitalizations and their causes will be carried out by telephone interview and by a review of admission data from hospital records.

Interventions

DEVICEA mechanical compression pump

Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.

Sponsors

Hillel Yaffe Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Hospitalized patients * Adults * Right heart failure secondary to pulmonary hypertension (cor pulmonale) * Pronounced leg edema

Exclusion criteria

* Patients in sepsis * Hemodynamically unstable * Renal failure (creatinine \>2 mg%) * Deep vein thrombosis * Pregnancy * Psychiatric/noncompliant patients * Patients who will not sign the informed consent form

Design outcomes

Primary

MeasureTime frame
Patient weight3 and 6 months

Secondary

MeasureTime frame
Leg circumference, Pulmonary pressures, Cardiac function3 and 6 months

Countries

Israel

Contacts

Primary ContactDavid S. Blondheim, MD
blond@netvision.net.il972-46304488

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026